Incyte Corporation (INCY)

[surf1944]

5:04PM Incyte announces that Phase III studies of Jakafi (ruxolitinib) published in The New England Journal of Medicine demonstrate significant clinical benefit for patients with myelofibrosis (INCY) 16.96 -0.14 : The New England Journal of Medicine today published results from two Phase III studies (COMFORT-I and COMFORT-II) of Jakafi (ruxolitinib), a JAK1 and JAK2 inhibitor recently approved by the FDA for the treatment of intermediate or high-risk myelofibrosis (MF). These data, which were included in the New Drug Application for Jakafi submitted by Incyte, showed that the treatment significantly reduced spleen volume and improved symptoms of MF. Additionally, in an updated analysis of COMFORT-I, treatment with Jakafi was associated with improved overall survival compared to placebo.